Research programme - cardiovascular disorder therapeutics - Elyson Pharma

Drug Profile

Research programme - cardiovascular disorder therapeutics - Elyson Pharma

Alternative Names: ELI 1501

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elyson Pharm
  • Class Anti-ischaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 17 Feb 2017 Preclinical trials in Cardiovascular disorders in South Korea before February 2017 (Elyson Pharm pipeline, February 2017)
  • 17 Feb 2017 Elyson Pharm announces intention to submit IND for ELI 1501 (Elyson Pharm pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top